OUR STORY
Our Vision
Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.
Learn more about us:
Ascelia Pharma Company Introduction – August 2023
TOP STORIES
Ascelia Pharma to Reach Headline Results from SPARKLE Re-Evaluation by May 2024 with Current Funding
2023-09-13 16:00:00
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the plan to complete, by May 2024, the […]
TOP STORIES
Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE
2023.08.08
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today reported the need for a re-evaluation of the collected […]
TOP STORIES
Ascelia Pharma achieves Last Patient Last Visit (LPLV) in the Orviglance Phase 3 SPARKLE Study which now includes 85 completed patients.
2023-03-03 10:07:00
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the Last Patient Last Visit (LPLV) has […]
Upcoming Events
Latest News
Presentations & Articles
INVESTOR
Shortcut to our latest Financial Reports
Key downloads
Half-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLEQUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completedCorrection: Ascelia Pharma publishes annual report for 2022Ascelia Pharma publishes annual report for 2022QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023.